

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

## Alectinib compared with chemotherapy in previously treated patients with ALK-positive NSCLC (ALUR)

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

**Trial Status**  
Completed

**Trial Runs In**  
15 Countries

**Trial Identifier**  
NCT02604342 2015-000634-29  
MO29750

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This randomized active-controlled multicenter Phase III open-label study will evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in participants with ALK-positive advanced NSCLC who were previously treated with chemotherapy and crizotinib, as measured by investigator-assessed progression-free survival (PFS) and to evaluate and compare between treatment groups the central nervous system (CNS) objective response rate (C-ORR) in participants with measurable CNS metastases at baseline, as assessed by an Independent Review Committee (IRC).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02604342 2015-000634-29 MO29750**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---